Eutilex Co (XKRX:263050) Total Liabilities : ₩24,046 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eutilex Co Total Liabilities?

Eutilex Co's Total Liabilities for the quarter that ended in Dec. 2024 was ₩24,046 Mil.

Eutilex Co's quarterly Total Liabilities increased from Jun. 2024 (₩13,643.96 Mil) to Sep. 2024 (₩13,768.59 Mil) and increased from Sep. 2024 (₩13,768.59 Mil) to Dec. 2024 (₩24,046.06 Mil).

Eutilex Co's annual Total Liabilities declined from Dec. 2022 (₩13,595.82 Mil) to Dec. 2023 (₩9,509.07 Mil) but then increased from Dec. 2023 (₩9,509.07 Mil) to Dec. 2024 (₩24,046.06 Mil).

Eutilex Co Total Liabilities Historical Data

The historical data trend for Eutilex Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eutilex Co Total Liabilities Chart

Eutilex Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

47,021.77

41,650.86

13,595.82

9,509.07

24,046.06

Eutilex Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															9,509.07	15,295.76	13,643.96	13,768.59	24,046.06

Eutilex Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eutilex Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18033.137	+	(2666.354	+	1070.039
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2074.486	+	202.042)
	=	24,046

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	66511.116	-	42465.058
	=	24,046

Eutilex Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18033.137	+	(2666.354	+	1070.039
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2074.486	+	202.042)
	=	24,046

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	66511.116	-	42465.058
	=	24,046

Eutilex Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Eutilex Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Eutilex Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eutilex Co Ltd (XKRX:263050) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Daeryung Technotown 17, Suite 1401, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, KOR, 08594

Website

http://www.eutilex.com

Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.

Eutilex Co Headlines

No Headlines